Search

Retinoblastoma risk factors for recurrence

This study evaluates risk factors for local tumour recurrence of main solid tumour, subretinal seed, vitreous seed and new tumour formation in eyes with retinoblastoma (RB) management with primary chemotherapy over 20 years of follow-up. The study included 960 eyes...

Long-term outcomes for hereditary retinoblastoma

Earlier diagnosis and more rigorous treatment regimens have contributed to better outcomes for patients with retinoblastoma. This study looked at 24 patients with hereditary bilateral retinoblastoma treated with systemic chemotherapy during a ten year period (2001-2011). The medical notes were...

Undetected retinoblastoma management following vitrectomy

This retrospective study from a single-centre referral university hospital in Germany analysed data collected between 1991-2019 to comment on management and complications of undetected retinoblastoma eyes following vitrectomy. The 10 patients included had a mean age of 36.1 months (range...

MicroRNA mediate retinoblastoma signal transduction

MicroRNAs (miR) are small non-coding single-stranded RNA molecules, normally 22 nucleotides long. There is a large family of miR that control protein expression by binding to mRNAs, leading to their degradation. One important role of miR is in tumours where...

RetCam use in differential diagnosis for retinoblastoma

The authors aimed to evaluate RetCam fundus photography and fluorescein angiography (FA) findings in pseudo retinoblastoma. This was a retrospective review of 36 eyes of 28 patients (of which six were female) with 22 bilateral cases. Mean age at presentation...

Saccades and contrast sensitivity in retinoblastoma survivors

The authors report a cross-sectional study, which recruited children aged 5 to 18 years old who completed treatment completion for retinoblastoma more than six months ago. Exclusion criteria included bilateral enucleation and pre-existing conditions associated with cognitive impairment. A total...

Episcleral brachytherapy (EB) for retinoblastoma (RB)

This retrospective study consisted of 11 eyes treated either with Iodine (I) -125 or Ruthenium (R) -106EB with a mean apical dose of 44Gy. There were five in group B (46%), three in group C (27%) and three in group...

SD-OCT detection of minimally visible retinoblastoma

This paper reports minimally visible tumour recurrence that was detectable on spectral domain OCT (SD-OCT) in a two-month old infant who had a diagnosis of bilateral familial retinoblastoma. The infant was treated with IVC for six cycles with vincristine, etoposide...

CSD-OCT detection of minimally visible retinoblastoma

This paper reports minimally visible tumour recurrence that was detectable on spectral domain OCT (SD-OCT) in a two-month-old infant who had a diagnosis of bilateral familial retinoblastoma. The infant was treated with IVC for six cycles with vincristine, etoposide and...

Primary intravenous chemotherapy (IVC) for Group D retinoblastoma

A retrospective review is reported of 64 group D retinoblastoma (RB) eyes (52 patients) treated with primary IVC, between 2002 and 2014 from two centres, in the UK and US. The median age at presentation was 11 months, 35 (67%)...

Analysis of needle site after intravitreal injection for retinoblastoma

This study analysed the needle washings from retinoblastoma (RB) eyes receiving intravitreal Melphalon to consider risk of tumour externalisation from the procedure – 280 injections to 63 eyes in 61 patients were evaluated. Unilateral RB was present in 24 patients...